Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02150967 · ClinicalTrials.gov registry record · Phase 2
A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma
A Phase 2 study, sponsored by QED Therapeutics, a BridgeBio company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 143
- Enrollment target
NCT02150967 is a Phase 2 study that was terminated before completion, run by QED Therapeutics, a BridgeBio company. The registered enrollment target is 143 participants.
The verdict
NCT02150967, a Phase 2 study, was terminated before completion, sponsored by QED Therapeutics, a BridgeBio company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 143 participants
- Enrollment target
Study Summary
This is a multi-center, open label, single arm phase II study evaluating BGJ398 (infigratinib) anti-tumor activity in advanced or metastatic cholangiocarcinoma patients with fibroblast growth factor receptor (FGFR) genetic alterations.
Interventions
- DRUG BGJ398 (infigratinib)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 143 participants |
| Start Date | 2014-07-23 |
| Est. Completion | 2022-02-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02150967
The ClinicalTrials.gov registry entry for NCT02150967 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 143 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is QED Therapeutics, a BridgeBio company, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BGJ398 (infigratinib) is the first listed.
NCT02150967 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02150967 about?
NCT02150967 is a clinical study titled "A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma". This is a multi-center, open label, single arm phase II study evaluating BGJ398 (infigratinib) anti-tumor activity in advanced or metastatic cholangiocarcinoma patients with fibroblast growth factor receptor (FGFR) genetic alterations.
What is the current status of trial NCT02150967?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 143 participants. The study started on 2014-07-23. Estimated completion is 2022-02-07.
What interventions are being tested in trial NCT02150967?
The interventions under investigation include: BGJ398 (infigratinib) (DRUG).
Who is sponsoring clinical trial NCT02150967?
This trial is sponsored by QED Therapeutics, a BridgeBio company, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.